
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2022-2027
Medical gadgets are items designed for human use and serving a medical purpose. In contrast to pharmaceuticals, which have pharmacological, immunological, or metabolic effects, medical devices' primary intended actions are typically delivered through physical means, such as force.
Implants, items for injection, infusion, transfusion, and dialysis, human medical tools, medical software, catheters, pacemakers, dental products, dressings, visual aids, X-ray equipment, condoms, medical instruments, and laboratory diagnostics are a few examples of medical devices.
Medical devices also include items that contain or are coated with substances or preparations of substances that, when used alone, are regarded as pharmaceuticals or pharmaceutical ingredients (including plasma derivatives) and have the potential to affect the human body in addition to the functions of the device.
The person should first evaluate the intended use (what the medical device performs) and indications for use (the ailment or disease the medical device will diagnose, cure, ameliorate, treat, or prevent) of the device to ascertain whether your product satisfies the FDA definition of a medical device.
The Italy Medical Devices market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2026, registering a CAGR of XX% from 2022 to 2027.
Ferrari and Fiat are in talks with producers of medical equipment to explore how they might help. The two Italian automakers have pledged to increase manufacturing of ventilators, one of the most important medical devices needed nationwide.
According to the article, Ferrari, Fiat Chrysler, and car parts producer Marelli are in talks with the Bologna-based Siare Engineering International Group to develop some parts, source others, and possibly even help assemble the lung ventilators.
These talks between Siare and the automakers aimed to evaluate and comprehend the viability of the two solutions listed below: help Siare increase production capacity at its own facility with assistance from FCA and Ferrari's technicians.
Following the conclusion of its fruitful pilot project, MedX Health Corp., a world authority in teledermatology, is happy to announce the signing of a commercial distribution deal with Vitamed Biomedical s.r.l. ("Vitamed").
Vitamed was able to better comprehend the patient journey and gauge market size and expectations thanks to the six-month experiment. According to the pilot's findings, dermatologists, pharmacists, and other Italian health care providers have a very high degree of approval for the MedX DermSecure Screening Platform.
I-VASC, an Italian manufacturer of medical devices, has announced the closure of a Series A investment for the introduction of its VELEX product. Empty Vein Ablation, a method of treating varicose veins and Chronic Venous Insufficiency (CVI), is possible using VELEX (EVA).
Compared to traditional sclerotherapy, VELEX offers greater safety. Determine market size and projections. According to the pilot's findings, dermatologists, pharmacists, and other Italian health care providers have a very high degree of approval for the MedX DermSecure Screening Platform.
Hemanext Inc., a pioneer in blood processing, storage, and transfusion technology, announced that it has signed distribution agreements with two of the top medical device distributors in the Nordics and Italy. This will help the company expand its sales into important European markets and strengthen its ties to the region's most important blood banks and doctors.
Versan & Dafne, a reputable distributor of medical equipment with a long history in Italy, will be an important ally in Hemanext's marketing plan for the Hemanext ONE system. Both businesses regularly collaborate with major hospitals and other healthcare institutes and have solid market positions in their niches.
As part of its plan for worldwide expansion, the Yorkshire-based regulatory affairs firm Woodley BioReg has established an Italian affiliate.Pharmaceutical, biopharmaceutical, healthcare, and medical device businesses can create and produce products that are efficient and secure for people all around the world with the assistance of Woodley BioReg.
Due to the effects of Brexit, Woodley BioReg has decided to establish a legal entity and new office in Italy. Several EC directives call for a European base for bringing products to the European market, something that Woodley BioReg was unable to provide directly to clients after the UK left the EU and had to rely on European partners.
The first implants in Europe for the recently introduced Optimizer Smart Mini device were just finished in Italy, according to Impulse Dynamics, a commercial-stage medical device business specializing in providing CCM therapy to patients with heart failure.
The new Optimizer Smart Mini system components, which include a rechargeable battery with a 20-year lifespan and new internal technology with improved programming and the potential for remote monitoring in a smaller design to make the implant procedure simpler for patients and doctors, are equally important across international markets.
The Optimizer Smart Mini administers CCM therapy, which uses electric pulses to stimulate the heart between beats to improve the efficiency of cardiac muscular contraction. This improves heart function without raising heart rate or cardiac muscle oxygen consumption.
TytoCare, thefirst all-in-one modular device and examination platform for AI-powered, on-demand, remote medicaltests,announced its launch in Italy,openingthedoorforwidespreadadoption of its telehealth solution.TytoCare willbeexclusivelyintroducedto the Italian public healthcare marketthrougharelationshipwith Multimed, atopdistribution and commercialization companyformedical devices, surgical instruments,robotics, and safety devices.
TytoCare is the onlyall-encompassingtelehealthservice that enables doctorsto remotely connect with patients forphysical examinationsofclinic-quality. Users of theportableexaminationtool candothoroughphysical examinations of the heart, skin, ears, throat, abdomen,lungs, and body temperature,allof which areessentialfor monitoring COVID-19.
For primary and chronic care settings, the solution perfectly simulates an in-person visit from any location, at any time, and by offering remote care for both isolated patients at home and quarantined patients in hospitals, it contributes to stopping the spread of the virus. This enables physicians to gather the crucial clinical information they need to remotely monitor and treat patients.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2022-2027 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2022-2027 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2022-2027 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2022-2027 |
21 | Product installation rate by OEM, 2022 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2022 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |